Inhibition of the Classical Complement Pathway by Synthetic Peptides from the Second Constant Domain of the Heavy Chain of Human Immunoglobulin G

Michael B. Prystowsky, J. Michael Kehoe, Bruce W. Erickson

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The Cγ2 domain of immunoglobulin G (IgG) is reported to have a tryptophan residue and cationic residues at or near its Clq-binding site. The present study has used synthetic IgG peptides to explore the involvement of the 275-290 region of the Cγ2 domain of the heavy chain of human IgGl in binding to Cl. This region (Phe-Asn-Trp-Tyr-Val-Asp-Gly-Val-Gln-Val-His-Asn-Ala-Lys-Thr-Lys) contains Trp-277 and the cationic residues His-285, Lys-288, and Lys-290. The following peptides were synthesized by the solid-phase method and purified to homogeneity by using reverse-phase high-pressure liquid chromatography: the hexadecapeptide 275-290 and its N'-formyl derivative 275-290F containing both Trp-277 and the Cationic residues; the Nα-acetylpentapeptide 275-279A comprising the hydrophobic region around Trp-277; and the cationic decapeptide 281-290. When examined in the Augener assay for inhibition of Clmediated immune hemolysis, peptides 275-290F and 281-290 were about half as active as monomeric 7S human IgG on a molar basis and essentially as active on a site basis. Since both peptides containing residues 281-290 inhibited hemolysis in a manner similar to the Cγ2 domain, the cationic 281-290 region containing His-285, Lys-288, and Lys-290 may be a part of the Clq-binding site of Cγ2. These results are consistent with the tertiary structure of the Fc fragment of IgG, in which the 275-279 region is part of the hydrophobic core of the Cγ2 domain and the 281-290 region is exposed on the surface.

Original languageEnglish (US)
Pages (from-to)6349-6356
Number of pages8
JournalBiochemistry
Volume20
Issue number22
DOIs
StatePublished - Oct 1981
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry

Fingerprint Dive into the research topics of 'Inhibition of the Classical Complement Pathway by Synthetic Peptides from the Second Constant Domain of the Heavy Chain of Human Immunoglobulin G'. Together they form a unique fingerprint.

Cite this